All In Biotech

Drug Trial Radar · NCT03548207

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 1b-2, Open-Label Study of JNJ-68284528, A Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

126

Actual

Start

Jun 29, 2018

Primary completion

Aug 23, 2022

Study completion Aug 23, 2022

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jun 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to characterize safety of JNJ-68284528 and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of JNJ-68284528 (Phase 2).

Conditions

  • Multiple Myeloma

Interventions

  • JNJ-68284528Biological

    JNJ-68284528 consist of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Number of Participants With Adverse Events as Per SeverityTime frame: Day 1 up to 45.2 months
  2. Phase 2: Overall Response Rate (ORR)Time frame: Day 1 up to 45.2 months

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Cancer Center-Scottsdale

    Phoenix, Arizona

  • City of Hope

    Duarte, California

  • University of California San Francisco

    San Francisco, California

  • University of Chicago

    Chicago, Illinois

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Mount Sinai Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Froedtert Memorial

    Milwaukee, Wisconsin

  • University Hospital Kyoto Prefectural University of Medicine

    Kyoto, Japan

  • Nagoya City University Hospital

    Nagoya, Japan

  • Hokkaido University Hospital

    Sapporo, Japan

  • Japanese Red Cross Medical Center

    Shibuya City, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.